Edition:
United Kingdom

Core Laboratories NV (CLB.N)

CLB.N on New York Stock Exchange

84.00USD
7:50pm GMT
Change (% chg)

$2.72 (+3.35%)
Prev Close
$81.28
Open
$81.24
Day's High
$84.30
Day's Low
$80.97
Volume
72,785
Avg. Vol
82,147
52-wk High
$130.34
52-wk Low
$80.27

Latest Key Developments (Source: Significant Developments)

Core Lab Reports Q3 2018 Results From Continuing Operations
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Core Laboratories NV ::CORE LAB REPORTS THIRD QUARTER 2018 RESULTS FROM CONTINUING OPERATIONS:.  Full Article

Core Laboratories NV Quarterly EPS Of $0.50
Wednesday, 24 Oct 2018 

Oct 24 (Reuters) - Core Laboratories NV ::CORE LABORATORIES NV QUARTERLY EPS OF $0.50 - SEC FILING.CORE LABORATORIES NV QUARTERLY EPS $0.64, EX-ITEMS.CORE LABORATORIES NV QUARTERLY REVENUE OF $182.1 MILLION, UP 12% YEAR-OVER-YEAR.CORE LABORATORIES NV SAYS FOURTH QUARTER 2018 OUTLOOK IS UNCHANGED FROM THE 8-K RELEASED ON OCTOBER 4, 2018.CORE LABORATORIES LP SAYS EXPECTS CONSOLIDATED Q4 REVENUE OF APPROXIMATELY $173.0 MILLION - $176.0 MILLION.CORE LABORATORIES NV SEES Q4 EPS OF $0.48 TO $0.54.  Full Article

Core Laboratories NV Qtrly GAAP EPS Of $0.57
Wednesday, 25 Jul 2018 

July 25 (Reuters) - Core Laboratories NV ::CORE LABORATORIES NV - QTRLY REVENUE OF $175.5 MILLION, UP 11% YEAR-OVER-YEAR.CORE LABORATORIES NV - QTRLY GAAP EPS OF $0.57.Q2 NON-GAAP EARNINGS PER SHARE $0.59.CORE LABORATORIES SEES Q3 2018 REVENUE ABOUT $177 MILLION TO $179 MILLION.CORE LABORATORIES SEES Q3 2018 EARNINGS PER SHARE ABOUT $0.64 TO $0.66.CORE LABORATORIES BELIEVES Q3 2018 INTERNATIONAL EXPLORATION AND PRODUCTION ACTIVITY LEVELS WILL BE FLAT TO UP SLIGHTLY, SEQUENTIALLY.CORE LABORATORIES NV - COMPANY'S OUTLOOK AND GUIDANCE IS UNCHANGED FROM THAT PROVIDED IN ITS 29 JUNE 2018 UPDATE.CORE LABORATORIES AVERAGE Q3 2018 U.S. RIG COUNT IS PROJECTED TO BE SLIGHTLY UP SEQUENTIALLY, WITH COMPLETION ACTIVITY LEVELS SHOWING MODEST GROWTH.  Full Article

Core Laboratories Expects Q2 EPS Of $0.57 To $0.59
Friday, 29 Jun 2018 

June 29 (Reuters) - Core Laboratories NV ::DEFERRED INTERNATIONAL ACTIVITY AFFECTS REVENUE OPPORTUNITIES; CORE LAB UPDATES Q2 2018 GUIDANCE.CORE LABORATORIES NV - ANNOUNCING REVISED GUIDANCE FROM CONTINUING OPERATIONS FOR Q2 2018 AND INITIATING GUIDANCE FOR Q3 2018.CORE LABORATORIES NV <<>> SEES Q2 SHR $0.57 TO $0.59.CORE LABORATORIES NV <<>> SEES Q3 SHR $0.64 TO $0.66.CORE LABORATORIES NV <<>> SEES Q3 REVENUE ABOUT $177 MLN TO $179 MLN.CORE LABORATORIES NV <<>> SEES Q2 REVENUE $174 MLN TO $175 MLN.CORE LABORATORIES- DELAYS IN RECOVERY OF INTERNATIONAL FIELD DEVELOPMENT ACTIVITY IMPACTING & DEFERRING REVENUE OPPORTUNITIES FOR RESERVOIR DESCRIPTION UNIT.CORE LABORATORIES - RESERVOIR DESCRIPTION INTERNATIONAL CLIENT PROJECT DISCUSSIONS CONTINUE TO INCREASE IN ALIGNMENT WITH ABOUT 15 FID'S ANNOUNCED YTD.CORE LABORATORIES NV - TOTAL NUMBER OF FID'S FOR 2018 IS EXPECTED TO EXCEED 20 FID'S IN 2017.CORE-ACTIVITY LEVELS, REVENUE OPPORTUNITY FROM 2018 FIDS, EMERGING INTERNATIONAL RECOVERY NOT EXPECTED TO HAVE POSITIVE IMPACT UNTIL LATE Q4 & THROUGH 2019.CORE - CONTINUES TO EXPECT QTRLY SEQUENTIAL IMPROVEMENTS THROUGHOUT 2018 IN REVENUE, OPERATING MARGINS, PROFITS, EPS.CORE LABORATORIES - NOW PROJECTS Q2 RESULTS WILL BE ONLY SLIGHTLY HIGHER THAN EXPERIENCED IN Q1.  Full Article

Core Laboratories NV Says On June 19, Co, Core Laboratories (U.S.) Interests Holdings Entered Seventh Amended And Restated Credit Agreement
Monday, 25 Jun 2018 

June 25 (Reuters) - Core Laboratories NV ::CORE LABORATORIES NV - ON JUNE 19, CO, CORE LABORATORIES (U.S.) INTERESTS HOLDINGS ENTERED SEVENTH AMENDED AND RESTATED CREDIT AGREEMENT.CORE LABORATORIES NV - UNDER AMENDED CREDIT AGREEMENT, AGGREGATE BORROWING COMMITMENT REDUCED UNDER EXISTING FACILITY TO $300 MILLION.CORE LABORATORIES NV - AMENDED CREDIT AGREEMENT PROVIDES OPTION TO INCREASE COMMITMENT UNDER CREDIT FACILITY TO $400 MILLION, IF CONDITIONS MET.CORE LABORATORIES NV SAYS AMENDED CREDIT AGREEMENT EXTENDS MATURITY OF REVOLVING CREDIT FACILITY FOR 5 YEAR PERIOD ENDING JUNE 19, 2024 - SEC FILING.  Full Article

Core Lab Q1 Revenue $170 Million
Wednesday, 25 Apr 2018 

April 25 (Reuters) - Core Laboratories NV ::CORE LAB REPORTS FIRST QUARTER 2018 RESULTS FROM CONTINUING OPERATIONS:.CORE LAB INITIATES Q2 2018 EPS GUIDANCE $0.64 TO $0.66.QTRLY REVENUE OF $170 MILLION, UP MORE THAN 8% YEAR-OVER-YEAR.QTRLY OPERATING MARGINS OF 19%, UP 400 BPS YEAR-OVER-YEAR.QTRLY GAAP EARNINGS PER SHARE OF $0.54.EXPECTS CONSOLIDATED Q2 2018 REVENUE OF APPROXIMATELY $177 MILLION TO $179 MILLION.QTRLY EARNINGS PER SHARE $0.57 EXCLUDING ITEMS.EXPECTS AVERAGE Q2 2018 U.S. RIG COUNT TO BE SLIGHTLY UP SEQUENTIALLY, WITH COMPLETION ACTIVITY LEVELS SHOWING MODEST GROWTH.Q1 EARNINGS PER SHARE VIEW $0.57, REVENUE VIEW $170.2 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $0.65, REVENUE VIEW $180.2 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Core Laboratories qtrly ‍revenue $166.2 mln vs $143.5 mln
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Core Laboratories NV : :Core Laboratories NV qtrly ‍revenue $166.2 million versus $143.5 million.Core Laboratories NV - qtrly earnings per share $0.48‍​.Core Laboratories NV - ‍eps for q4 2017 is expected to be approximately $0.58​.Core Laboratories NV sees Q4 2017 revenue of approximately $171.5 million.Q4 earnings per share view $0.58, revenue view $171.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $0.44, revenue view $161.4 million -- Thomson Reuters I/B/E/S.  Full Article

Core Laboratories CEO David Demshur's 2016 total compensation was $6.2 mln
Friday, 24 Mar 2017 

Core Laboratories Nv - :CEO David Demshur's fy 2016 total compensation was $6.2 million versus $6.6 million in fy 2015 - sec filing.  Full Article